共 50 条
- [1] Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC)JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Davelaar, JohnBrown, ZachariahLinden, SheilaRodriguez, ChristinaElmadbouh, OmerPachter, Jonathan A.Gong, JunHendifar, Andrew EugeneLo, SimonGaddam, SrinivasNissen, NicholasBurkhart, Richard A.Zheng, LeiOsipov, Arsen
- [2] A phase II trial of preoperative FOLFIRINOX followed by gemcitabine-based chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma (BR PDAC).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Wysota, MichaelJirgal, AmandaAcuna-Villaorduna, AnaViswanathan, ShankarKaubisch, AndreasGadde, EswarKabarriti, RafiGoel, SanjayChuy, Jennifer W.
- [3] Prospective trial of preoperative FOLFIRINOX in patients with resectable pancreatic ductal adenocarcinoma (PDAC): Report of early endpoints.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Shahda, SafiHouse, Michael GarrettZyromski, Nicholas J.Sehdev, AmikarCramer, Harvey M.Flynn, JanetAkisik, FatihCeppa, Eugene P.Schmidt, C. MaxNakeeb, AttilaLin, JingmeiPerkins, Susan M.Burney, HeatherO'Neil, Bert H.
- [4] Preoperative chemoradiation for resectable adenocarcinoma of pancreatic head: results of a randomized phase-II trialSTRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 : 18 - 18Brunner, T. B.Golcher, H.Witzigmann, H.Marti, L.Bechstein, W. -OBruns, C.Jungnickel, H.Schreiber, S.Grabenbauer, G. G.Meyer, T.Merkel, S.Fietkau, R.Hohenberger, W.
- [5] Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA4132 - LBA4132Weinberg, Benjamin AdamLekan, AlexanderFitzgerald, AllisonMalchiodi, ZoeGutierrez, MartinTesfaye, Anteneh A.Tan, Ming TonyNoel, Marcus SmithHe, Aiwu RuthMukherji, ReetuMarshall, JohnJones, PrincessBorderies, PascalONeill, VincentWeiner, Louis M.
- [6] A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaCLINICAL CANCER RESEARCH, 2024, 30 (20) : 4609 - 4617Coveler, Andrew L.Reilley, Matthew J.Zalupski, MarkMacarulla, TeresaFountzilas, ChristosPonz-Sarvise, MarianoNagrial, AdnanUboha, Nataliya V.Frentzas, SophiaOverman, MichaelNoonan, AnneMessersmith, Wells A.Pavlakis, NickMettu, Niharika B.Bisha, InaWang, YingSmith, PaulMurtomaki, ElinaBielska, Agata A.Bragulat, VeroniqueCooper, Zachary A.Kumar, RakeshSpigel, David R.
- [7] A randomized phase II study of cabiralizumab (cabira) plus nivolumab (vivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)Wang-Gillam, AndreaO'Reilly, Eileen MaryBendell, Johanna C.Wainberg, Zev A.Borazanci, Erkut HasanBahary, NathanO'Hara, Mark H.Beatty, Gregory LawrencePant, ShubhamCohen, Deirdre JillLeong, StephenBeg, Muhammad ShaalanYu, Kenneth H.Evans, T. R. JeffrySeufferlein, ThomasOkusaka, TakujiPhillips, PennyLiu, XuanPerna, Serena K.Le, Dung T.
- [8] Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical TrialJAMA ONCOLOGY, 2019, 5 (10) : 1431 - 1438O'Reilly, Eileen M.Oh, Do-YounDhani, NeeshaRenouf, Daniel J.Lee, Myung AhSun, WeijingFisher, GeorgeHezel, AramChang, Shao-ChunVlahovic, GordanaTakahashi, OsamuYang, YinFitts, DavidPhilip, Philip Agop
- [9] Randomized phase II study of WT1 peptide vaccine plus gemcitabine for advanced pancreatic ductal adenocarcinoma (PDAC): Clinical efficacy and immune responseJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Nishida, SumiyukiIshikawa, TakeshiKokura, SatoshiEgawa, ShinichiKoido, ShigeoYasuda, HiroakiYanagimoto, HiroakiIshii, JunKanno, YoshihideOba, Mari SaitoSato, MahoMorimoto, SoyokoEguchi, HidetoshiNagano, HiroakiHomma, SadamuOka, YoshihiroMorita, SatoshiSugiyama, Haruo
- [10] Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trialEUROPEAN JOURNAL OF CANCER, 2024, 196Melisi, DavideZecchetto, CamillaMerz, ValeriaMalleo, GiuseppeLandoni, LucaQuinzii, AlbertoCasalino, SimonaFazzini, FedericaGaule, MarinaPesoni, CamillaCasetti, LucaEsposito, AlessandroMarchegiani, GiovanniPiazzola, CristianaD'Onofrio, Mirkode Robertis, RiccardoGabbrielli, ArmandoBernardoni, LauraCrino, Stefano F.Pietrobono, SilviaLuchini, ClaudioAliberti, CamilloMartignoni, GuidoMilleri, StefanoButturini, GiovanniScarpa, AldoSalvia, RobertoBassi, Claudio